From Riyadh to United States: How a 17-Year-Old's Family Refused to Accept One Treatment Plan for Metastatic Osteosarcoma
- Medebound HEALTH
- 1 day ago
- 11 min read
Introduction
When Ziad's parents sat in a clinic in Riyadh in March 2026, they understood the words the doctor was saying — but they could not yet absorb them. Their 17-year-old son, a teenager from Saudi Arabia who had been complaining of knee pain for barely two months, had been diagnosed with metastatic osteosarcoma — an aggressive bone cancer that had already spread to multiple sites throughout his skeleton.
Ziad (a pseudonym used to protect his privacy) had been healthy his entire life. No prior medical history, no family history of cancer. He was 17, in his final years of secondary school, 176 cm tall, and otherwise in good physical condition. Then came January 2026, and a nagging ache above his right knee that would not go away.
Within weeks, the ache had become swelling. The swelling became pain severe enough to confine him to bed. By the time imaging confirmed what the family feared most, the cancer had already traveled — to his left shoulder, his ribs, his spine, his pelvis, and his right tibia. It was a devastating picture. And yet, faced with that picture, Ziad's family did not simply accept the first treatment plan they were handed. They asked whether there was more to know.
"We wanted to understand every option available to him. He is 17. We owed him that."
This is the story of how that decision — to seek an international specialist review through Medebound HEALTH— brought the family a clearer roadmap forward, and what it means for families in similar situations around the world.
The Diagnosis: What the Scans Revealed
Ziad's symptoms began in mid-January 2026 with mild pain in the distal right femur — the lower portion of the thigh bone, just above the knee. He was initially seen locally and managed with over-the-counter pain relief. But the pain did not respond.
By February 2026, visible swelling had developed around his upper knee, spreading upward toward the femur. The pain had become severe enough at night to prevent sleep, and Ziad required bed rest for approximately fifteen days. Multiple courses of anti-inflammatory medications provided no meaningful relief. An MRI was ordered.
On March 7, 2026, the MRI of the right knee revealed a large, inhomogeneous mass in the distal femur measuring approximately 91 × 81 × 92 mm — roughly the size of a lemon — with features including a distinctive "onion peel" periosteal reaction (a layered bone reaction around the tumor visible on imaging) and signal patterns strongly suggesting osteosarcoma, a primary bone cancer most commonly seen in adolescents and young adults.
Three days later, on March 10, a whole-body PET-CT scan — a combined imaging technique using a radioactive tracer to identify areas of high metabolic activity associated with cancer — confirmed the extent of the disease. The primary lesion in the distal right femur measured 74 × 73 × 124 mm with an SUV Max of 16.9, indicating very high metabolic activity consistent with aggressive malignancy. Multiple additional lesions showing high FDG avidity were identified at the left humeral head (left shoulder), right 7th rib, dorsolumbar vertebrae (mid-to-lower spine), sacrum (base of the spine), proximal right femur, and proximal right tibia. The lungs were clear.
A CT-guided biopsy on March 13, 2026 confirmed the diagnosis. Microscopic pathology showed an osteoid-forming neoplasm with significant atypia — in plain terms, tumor cells actively producing abnormal bone material, a hallmark of osteosarcoma. The pathological conclusion was unambiguous: osteosarcoma.
On March 23, 2026, Ziad's treating oncologist at a major academic medical center in Riyadh — a specialist in medical oncology with extensive experience in sarcoma — reviewed the full diagnostic picture and reached a clinical judgment. Given the metastatic nature of the disease, curative intent was not considered feasible. The recommendation was palliative single-agent chemotherapy with doxorubicin (Adriamycin) at 75 mg/m², a standard approach aimed at controlling disease progression and managing symptoms rather than achieving a cure.
Ziad began his first cycle of chemotherapy on March 23, 2026. He tolerated it without major complications — no Grade III or IV toxicities. His second cycle followed on April 13, 2026, with similar tolerability. A second local opinion, obtained on April 6, 2026 from a sarcoma specialist at a leading hospital in Riyadh, concurred with the single-agent palliative approach, noting that adding further agents might increase complications without proportionate benefit at this stage.
The family had two consistent opinions from experienced Saudi oncologists. Both pointed in the same direction: palliation. But they still had one question no one had answered to their satisfaction — had every option truly been considered?
Why They Decided to Look Further
For Ziad's family, the decision to seek an international second opinion was not a rejection of the care they had received. The oncologists who had treated Ziad were experienced and had been direct with them — a quality the family explicitly valued. But metastatic osteosarcoma in a 17-year-old carries such profound stakes that the family felt they needed to hear from a specialist whose entire career had focused on exactly this type of cancer.
Several specific questions weighed on them. The initial pathology had noted features of parosteal osteosarcoma — a lower-grade subtype that typically carries a better prognosis — yet the imaging showed the aggressive spread pattern of high-grade disease. They wanted to understand this apparent discrepancy. They also wanted to know whether there were systemic therapy options beyond single-agent doxorubicin that might be appropriate, and whether any clinical trials were available that Ziad might qualify for.
"The local doctors never said the wrong thing — they gave us their honest assessment. But Ziad is young. We needed to be sure we hadn't missed something."
A family member researching their options online came across Medebound HEALTH, a cross-border medical consulting service that arranges specialist second-opinion reviews with oncologists at leading U.S. cancer centers. The prospect of having Ziad's records reviewed by a physician who specialized specifically in osteosarcoma — at one of the most recognized cancer institutions in the world — addressed exactly what they were looking for. They initiated contact, submitted Ziad's complete medical records, and waited.
If you have received a complex diagnosis and want a specialist review from a US physician, our team can explain the process and help you understand your options — at no cost. |
How the Process Worked
The submission process through Medebound HEALTH required Ziad's family to compile and share his complete medical documentation: the MRI reports from March 7 and March 11, the whole-body PET-CT report from March 10, the biopsy pathology report from March 13, the chemotherapy prescriptions and tolerance records from both cycles, the clinical case summary, and the two prior specialist opinions from his treating oncologists in Saudi Arabia.
The family also submitted nine specific clinical questions they wanted addressed — ranging from the prognosis and quality-of-life implications of the current palliative approach, to whether combination chemotherapy regimens should be considered, to the role of surgery or radiation in his situation, to the availability of clinical trials.
Medebound HEALTH coordinated the review with Dr. Kumar (a pseudonym assigned in accordance with our privacy policy), a board-certified medical oncologist currently appointed at Sarcoma Center at The University of Texas MD Anderson Cancer Center in Houston — one of the first three comprehensive cancer centers designated under the 1971 U.S. National Cancer Act and consistently ranked among the top cancer hospitals in the United States. Dr. Kumar holds a tenured professorship in medicine and a named research chair in cancer research, has authored or co-authored over 250 peer-reviewed publications, has contributed to multiple editions of Harrison's Textbook of Internal Medicine, and has served as president of the Connective Tissue Oncology Society (CTOS) as well as chair of the Medical Advisory Board of the Chordoma Foundation. His clinical research focuses specifically on systemic therapies for sarcomas and primary bone malignancies.
The written specialist report was returned to the family within the agreed consultation window. It addressed each of their nine questions in structured, clinician-to-clinician clinical language, accompanied by a clear overall treatment algorithm — a step-by-step framework for how to approach Ziad's care over time.
What the Specialist's Review Revealed
Dr. Rajan's written assessment began with an important clarification about Ziad's pathology. The biopsy had noted features potentially consistent with parosteal osteosarcoma — a low-grade subtype that typically does not spread aggressively. However, Dr. Rajan's review of the full clinical picture — particularly the widespread bone metastases — led to a clear conclusion: regardless of what the initial biopsy suggested, the disease behavior was consistent with high-grade (dedifferentiated) osteosarcoma. In plain terms, even if the tumor had begun as a lower-grade subtype, it had undergone a transformation into a more aggressive cancer, which explained the pattern of spread.
This distinction matters clinically because it shapes both the treatment approach and the prognosis framework. High-grade metastatic osteosarcoma is not typically curable, but Dr. Kumar was clear that it can be meaningfully controlled using multiple established systemic therapy options — an important qualification that went beyond the framing the family had received to that point.
The Clinical Comparison: Treatment Approaches
Clinical Dimension | Current Plan (Riyadh) | MD Anderson Specialist's Input |
Disease Classification | Metastatic osteosarcoma (parosteal features noted) | High-grade osteosarcoma with likely dedifferentiation; parosteal features do not explain the metastatic pattern |
Current Chemotherapy | Single-agent doxorubicin 75 mg/m² (palliative intent) | Single-agent doxorubicin is an appropriate first-line option; if patient is in good general condition, consider combination regimen (e.g., doxorubicin + cisplatin) for increased response probability |
Goal of Treatment | Disease control and quality of life (palliative) | Disease control with potential for durable response; curative intent not likely but meaningful remission is achievable |
Second-Line Options | Oral metronomic therapy after doxorubicin; PET-CT reassessment | Sequential single agents: cisplatin, ifosfamide, high-dose methotrexate (2nd, 3rd, 4th line); gemcitabine + docetaxel as salvage combination |
Targeted Therapy | Not discussed at this stage | VEGFR inhibitors (regorafenib or cabozantinib) as future salvage after standard chemotherapy exhaustion |
Surgery / Radiation | Local decision to follow after PET-CT reassessment (palliative intent only) | Surgery for pain control only at specific progressing sites; radiation as alternative; surgical removal of all sites not practical |
Clinical Trials | Not discussed | Not recommended until standard options exhausted; three specific trials at MD Anderson identified as potential future options |
Monitoring Plan | PET-CT after several doxorubicin cycles | PET-CT every 2–3 months for ongoing disease monitoring plus symptomatic supportive care |
Individual results will vary. The outcome described reflects this patient's specific clinical circumstances. Speak with your own physician to understand what results may be realistic for your situation.
Among the most substantive additions in Dr. Kumar's assessment was the outline of a structured treatment algorithm — a prioritized sequence of therapeutic options from first line through to salvage. This gave Ziad's family and treating physicians a documented roadmap: what to try first, what comes next if that fails, and at what point emerging options such as clinical trials become relevant.
Specifically, Dr. Kumar identified three clinical trials that may merit consideration if Ziad's disease progresses through standard chemotherapy: a combination immunotherapy/targeted therapy trial (NCT05019703, Atezolizumab + Cabozantinib), a CAR-NK cell therapy trial (NCT05703854), and a targeted kinase inhibitor trial (NCT07193550, Zanzalintinib/XL092). These were noted as future options, to be evaluated at the appropriate time once updated scan results are available.
On the question of pathology, Dr. Kumar also pointed to an important clinical nuance: if the original biopsy truly indicated low-grade parosteal osteosarcoma, the presence of widespread bone metastases could only be explained by dedifferentiation — a process in which a lower-grade tumor transforms into a higher-grade one over time. This finding, if confirmed by further pathological review, would be clinically significant because it affects both prognosis and the selection of chemotherapy agents.
The specialist's overall assessment, in his own words from the written report: "Not likely to be curable, but can be controlled with several systemic therapy options." This framing — honest about prognosis, but explicit about the range of available options — was exactly what the family had been seeking.
What the Family Did With the Information
Ziad's family did not make any immediate changes to his treatment plan upon receiving the second opinion. Instead, they shared the report with his treating oncologist in Riyadh — whose opinion they continued to value and who remained Ziad's primary physician. The second opinion was presented not as a counter-argument but as supplementary expert input from a specialist in the same field.
The most immediate practical benefit was the treatment algorithm. Ziad's oncologist now had a documented framework from a senior sarcoma specialist at a leading U.S. cancer center, outlining the preferred sequencing of chemotherapy agents and the conditions under which salvage therapies and clinical trials should be considered. This gave the clinical team in Saudi Arabia a broader evidence base for ongoing decision-making.
The family is also aware that if Ziad's disease progresses through standard chemotherapy, the clinical trials identified by Dr. Kumar at MD Anderson Cancer Center represent a documented next step they can revisit at the appropriate time.
Like Ziad's Family, Are You Weighing a Significant Medical Decision? If you or someone you care for has received a complex oncology diagnosis and you'd like expert input from a specialist in bone and soft tissue cancers — Request Your Free Case Review → |
Clinical Timeline
Date | Event |
Mid-Jan 2026 | Onset of mild pain in the distal right femur; managed with analgesics following local consultation |
February 2026 | Progressive swelling above the knee; increased pain, restricted mobility; ~15 days bed rest required; nocturnal pain reported |
March 7, 2026 | Right knee MRI: 91 × 81 × 92 mm mass in distal femur; onion peel periosteal reaction; highly suspected osteosarcoma |
March 10, 2026 | Whole-body PET-CT: primary lesion 74 × 73 × 124 mm, SUV Max 16.9; multiple skeletal metastases confirmed; lungs clear |
March 11, 2026 | Enhanced MRI of the right leg: 73 × 87 × 86 mm lesion in distal femoral metaphysis; findings consistent with osteosarcoma |
March 13, 2026 | CT-guided biopsy: osteoid-forming neoplasm with significant atypia; pathological conclusion — osteosarcoma |
March 23, 2026 | First-line palliative chemotherapy commenced: single-agent doxorubicin 75 mg/m²; 1st cycle completed without major complications |
April 6, 2026 | Second local opinion (Riyadh specialist): agreement with palliative single-agent approach; PET-CT reassessment recommended after several cycles |
April 13, 2026 | 2nd cycle of doxorubicin chemotherapy; good tolerance; no Grade 3/4 toxicities; patient clinically stable |
May 1, 2026 | Medebound Health specialist review completed by sarcoma oncologist at MD Anderson Cancer Center; structured treatment algorithm and clinical trial options provided |
At the time of publication, Ziad is continuing his chemotherapy regimen under the care of his treating oncologist in Riyadh. He is clinically stable, maintaining a good performance status, and has tolerated two cycles of chemotherapy without serious adverse events. His case is being monitored with PET-CT imaging planned to assess response after further cycles.
The specialist review from MD Anderson has been incorporated into his ongoing care planning. His treating physician now has a documented second opinion and a structured treatment algorithm from a sarcoma specialist, which will inform decisions about next-line therapy if his disease progresses.
How Medebound HEALTH Connects International Patients to Top U.S. Cancer Experts
Medebound HEALTH is a U.S.-based medical coordination service that facilitates second opinions from independent U.S.-licensed physicians affiliated with leading cancer centers such as MD Anderson, Mayo Clinic, Memorial Sloan Kettering and Johns Hopkins. Since 2016, the service has supported 3000+ international patients, primarily from Asia, seeking expert input before major oncology decisions.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Is a Second Opinion Right for Your Situation?
If you or someone in your family has received a diagnosis that feels uncertain, a treatment plan that raises questions, or a disease that has returned or changed—you do not have to navigate that alone.
A 20-minute, no-obligation case review with a Medebound HEALTH Advisor will help you understand whether a specialist review is appropriate for your situation, which type of specialist would be most relevant, and what the process involves, step by step. There is no pressure and no commitment. The conversation begins with your questions.
Disclaimer
We strive to maintain the accuracy and provide regular updates for the treatment information described in this article. However, treatment outcomes may vary between individuals. The information provided here is not intended as a diagnostic or treatment recommendation and should not replace the careful evaluation and advice of your attending physician. The service is independently operated by Medebound HEALTH and is not provided, partnered, or affiliated with any hospital center as an institution.
